Press Releases

Press Releases

January 24, 2024
CytomX Therapeutics Announces FDA Clearance of IND Applications for CX-2051, a Probody® Antibody Drug Conjugate (ADC) Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b
- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma also anticipated in 1H 2024 - SOUTH SAN
Additional Formats
January 4, 2024
CytomX Therapeutics Outlines 2024 Company Priorities and Milestones
- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data anticipated in  the 2 nd half of 2024 - - IND application filed for conditionally activated EpCAM-directed ADC (CX-2051) with Phase 1 initiation in EpCAM positive tumors expected in the 1 st half of 2024   - - IND application
Additional Formats
Displaying 11 - 17 of 17